Catalyst ligands

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.2304-30-5,Tetrabutylphosphonium chloride,as a common compound, the synthetic route is as follows.

EXAMPLE 1 Preparation of 4-(chloroacetyloxy)benzene sulfonic acid, sodium salt. A slurry of 69.6 g (0.30 mole) of 4-hydroxybenzenesulfonic acid, sodium salt dihydrate, and 600 mL of mixed xylenes was heated to reflux for four hours with azeotropic removal of a total of 100 mL of xylenes and water using a Dean-Stark trap. The mixture was allowed to cool to 60 C. and 2.04 g (0.006 mole) of tetra-n-butylphosphonium chloride was added followed by 26.8 mL (0.33 mole) of chloroacetyl chloride. The mixture was heated to reflux for six hours and then allowed to cool to room temperature. The white solid product was collected by filtration, washed with 100 mL of toluene and dried at 50 to 60 C. under reduced pressure to give 80.1 g of product 1 H NMR (DMSO-d6, 300 MHz) indicated a 50:1 mixture of 4-(chloroacetyloxy)benzenesulfonic acid, sodium salt, and 4-hydroxybenzenesulfonic acid, sodium salt: delta4.71 (s, 2 H, CO2 CH2 Cl), 7.14 (d, 2 H, J=8.8 Hz), 7.68 (d, 2 H, J=8.8 Hz)., 2304-30-5

As the paragraph descriping shows that 2304-30-5 is playing an increasingly important role.

Reference£º
Patent; E. I. Du Pont de Nemours and Company; US4985180; (1991); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.131833-89-1,(S,S)-4,4′-Diisopropyl-4,5,4′,5′-tetrahydro[2.2]bioxazolyl,as a common compound, the synthetic route is as follows.

To a suspension of silver(I) triflate (415 mg, 1.62 mmol) in CH2Cl2 (5 mL) was added chloromethyl pivalate (243 mg, 1.62 mmol) and the resulting suspension stirred for 45 min. The supernatant was transferred to the bisoxazoline (250 mg, 1.12 mmol) and the mixture stirred at 40 C in the dark in a sealed Schlenk tube for 24 h. After cooling to ambient temperature, the reaction was quenched with MeOH (5 mL) and the mixture was concentrated in vacuo to afford a brown oil. Chromatographic purification (5% MeOH/CH2Cl2) and subsequent recrystallisation from CH2Cl2/Et2O gave the title compound 43 as a colourless solid (264 mg, 61%). inlMMLBox (c 0.5, CH2Cl2), lit.33 +55.0 (c 1.0, CH2Cl2); mp¡ì 155-157 C; deltaH (400 MHz, CDCl3) 8.73 (1H, s, NCHN), 5.07 (2H, dd, J 9.0, 7.9, CH2O), 4.98-4.93 (2H, m, CHCH2O), 4.83 (2H, dd, J 9.0 and 4.1, CH2O), 2.35-2.31 (2H, m, CHCH3), 1.03 (6H, d, J 6.9, CH3), 0.99 (6H, d, J 6.9, CH3); deltaC (100 MHz, CDCl3) 125.6 (NCO), 120.6 (q, J 321, CF3), 116.3 (NCHN), 79.1 (CH2), 63.9 (CHCH2), 31.1 (CHCH3), 17.6 (CH3) and 16.7 (CH3); 19F NMR (273 MHz, CDCl3) -78.6 (CF3). Data are in accordance with the literature.33, 131833-89-1

131833-89-1 (S,S)-4,4′-Diisopropyl-4,5,4′,5′-tetrahydro[2.2]bioxazolyl 11147594, acatalyst-ligand compound, is more and more widely used in various.

Reference£º
Article; Campbell, Craig D.; Concellon, Carmen; Smith, Andrew D.; Tetrahedron Asymmetry; vol. 22; 7; (2011); p. 797 – 811;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1067-33-0,Dibutyltin diacetate,as a common compound, the synthetic route is as follows.

[Example 6] 221 g of di-n-butyl tin diacetate and 515 g of 2-ethyl-1-butanol (guaranteed reagent, Wako Pure Chemical Industries, Ltd., Japan) were placed in a 2 L volumetric eggplant-shaped flask in a nitrogen atmosphere at atmospheric pressure, and the flask was attached to a rotary evaporator to which was connected an oil bath equipped with a temperature controller, a vacuum pump and a vacuum controller. The purge valve outlet of the rotary evaporator was connected to a line containing nitrogen gas flowing at atmospheric pressure. After replacing the inside of the system with nitrogen, the temperature of the oil bath was set to be 140C, the flask was immersed in the oil bath and rotation of the rotary evaporator was started. A low boiling point component was distilled off for about 7 hours in the presence of nitrogen at atmospheric pressure with the purge valve of the rotary evaporator left open, after which the pressure in the system was gradually reduced, and residual low boiling point component was distilled off with the pressure inside the system at 76 to 10 kPa. When the low boiling point component fraction no longer appeared, the flask was removed from the oil bath and allowed to cool. 274 g of residual liquid were obtained in the flask. Based on the results of 1H- , 13C- and 119Sn-NMR analyses, the residual liquid in the flask was a solution containing 96.0% by weight of di-n-butyl-bis(2-ethylbutyloxy) tin. On the other hand, 563 g of low boiling point component were recovered. When analyzed by gas chromatography, the low boiling point component contained about 30.9% by weight of (2-ethylbutyl) acetate., 1067-33-0

As the paragraph descriping shows that 1067-33-0 is playing an increasingly important role.

Reference£º
Patent; Asahi Kasei Chemicals Corporation; EP2226328; (2010); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.103946-54-9,4′-Methyl-[2,2′-bipyridine]-4-carboxylic acid,as a common compound, the synthetic route is as follows.

300 mg (1.4 mmol) of 4-methyl-4′-carboxy-2,2′-bipyridine was weighed out296 mg (1.64 mmol) of 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (EDC ¡¤ HCl) and 161 mg (1.4 mmol) of N-hydroxysuccinimide (NHS) , Evacuated and protected by nitrogen. Then, 6 mL of dry DMF and 0.4 mL of dry triethylamine were added to react for 12 h at 25 C., 1.5 mL of ethylamine and 0.6 mL of triethylamine were added, and the reaction was continued at 25 C. for 24 h. The reaction was completed and the residue was evaporated under reduced pressure. The residue was taken up in dichloromethane (3 ¡Á 100 mL) and the organic phase was spin-dried and packed in silica gel. The product was isolated and purified in 30% yield

103946-54-9, As the paragraph descriping shows that 103946-54-9 is playing an increasingly important role.

Reference£º
Patent; Nanjing University of Posts and Telecommunications; Zhang Yin; Zhang Taiwei; Sun Guanglan; Gao Pengli; Chen Xiaojiao; Zhao Qiang; Liu Shujuan; Huang Wei; (16 pag.)CN107417737; (2017); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

4479-74-7, 2,2-Bipyridine-6,6-dicarboxylic Acid is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

The organic ligands L, Ru (DMSO) 4Cl2,6,6′-dicarboxy-2,2′-bipyridine were dissolved in a molar ratio of 1: 1: 0.5In (1mL per millimol of organic ligand L) methanol, incubated at 50 for 76 hours, cooled to room temperature, to obtain bimetallicRu supramolecular macrocycle.

4479-74-7, As the paragraph descriping shows that 4479-74-7 is playing an increasingly important role.

Reference£º
Patent; Shandong Normal University; Dong Yubin; Zhang Jinping; Ma Jianping; (11 pag.)CN104558050; (2017); B;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

4479-74-7,With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.4479-74-7,2,2-Bipyridine-6,6-dicarboxylic Acid,as a common compound, the synthetic route is as follows.

General procedure: A mixture of Tb(NO3)3¡¤6H2O (0.045 g, 0.10 mmol), H2bpdc (0.024 g, 0.10 mmol) in distilled water (10 mL) that adjusted the pH value to 2.5 with 0.5 mol L-1 NaOH aqueous solution. It was then sealed in a 25 mL Teflon reactor and heated at 160 C for 72 h, and then cooled to ambient temperature at a rate of ca.2 C h-1 to give colorless block crystals of 7, yield: 57% based on H2bpdc.

The synthetic route of 4479-74-7 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Ren, Ya-Lan; Wang, Fei; Hu, Huai-Ming; Chang, Zhuguo; Yang, Meng-Lin; Xue, Ganglin; Inorganica Chimica Acta; vol. 434; (2015); p. 104 – 112;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.485-71-2,Cinchonidine,as a common compound, the synthetic route is as follows.,485-71-2

General procedure: The alkaloid (12.3 mmol, 1 eq.) and the appropriate substituted benzylic halide derivative(12.3 mmol, 1 eq.) were dissolved in THF (40 mL) with addition of a trace of NaI. The mixture washeated to reflux overnight and then cooled and stirred at ambient temperature for 1 h. In most cases theproduct precipitated as an off-white solid, but where this was not the case and the mixture containedonly a small amount of solid or no solid at all, then diethyl ether (20 mL) was added dropwise.The solid was removed via filtration and washed with THF (50 mL) or ether:THF, (1:1, v/v, 50 mL)and was dried under reduced pressure at 40 C. Where the solid formed was not a fine powder it was then taken up in DCM and this solution was then added dropwise to rapidly stirring ether (100 mL).This usually gives a finely divided solid that could be filtered and dried. (Note: The cinchonine derivedPTCs are usually very insoluble. The quinidine derived PTCs are often completely soluble at the endof the reaction.) The di(t-butyl)benzyl PTC was prepared according to the standard procedure aboveand was filtered directly from the reaction mixture.

485-71-2 Cinchonidine 101744, acatalyst-ligand compound, is more and more widely used in various.

Reference£º
Article; Zhang, Tao; Scalabrino, Gaia; Frankish, Neil; Sheridan, Helen; Molecules; vol. 23; 7; (2018);,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI